Mounjaro vs Trulicity: Long-Term Durability of Response

How These Two Drugs Work Differently

Tirzepatide activates both the glucose-dependent insulinotropic polypeptide (GIP) receptor and the GLP-1 receptor simultaneously. Dulaglutide acts only on the GLP-1 receptor. That mechanistic difference matters for long-term response because GIP receptor co-agonism adds an independent anabolic and insulinotropic signal that GLP-1 alone cannot replicate.

Tirzepatide's Dual-Receptor Mechanism

The GIP receptor pathway amplifies insulin secretion in a glucose-dependent manner and may reduce glucagon secretion more than GLP-1 alone 1. In rodent models, GIP receptor agonism also increased adipose lipid storage efficiency, which initially seemed counterproductive, but in humans the net metabolic result is greater fat mass reduction and better beta-cell preservation over time 2.

Dulaglutide's GLP-1-Only Pathway

Dulaglutide is a long-acting GLP-1 receptor agonist fused to an Fc immunoglobulin fragment for a half-life of roughly 5 days 3. It slows gastric emptying, reduces appetite, and stimulates insulin secretion in a glucose-dependent way. Those effects are real and clinically meaningful, particularly for patients who cannot tolerate the gastrointestinal side effects of more potent agents.

Why Mechanism Predicts Durability

Beta-cell function declines in type 2 diabetes at roughly 5% per year 4. Drugs that preserve or partially restore beta-cell mass tend to show less glycemic drift over time. Tirzepatide's dual agonism produces a larger initial beta-cell secretory reserve improvement than dulaglutide in head-to-head data, which is one plausible explanation for its more durable HbA1c response 1.

SURPASS-2: The Definitive Head-to-Head Trial

SURPASS-2 (N=1,879) remains the only large randomized controlled trial comparing tirzepatide directly to dulaglutide in adults with type 2 diabetes inadequately controlled on metformin 1. Published in the New England Journal of Medicine in 2021, it ran for 40 weeks.

Primary Glycemic Results

All three tirzepatide doses outperformed dulaglutide 1.5 mg on the primary endpoint of HbA1c change from baseline 1:

| Arm | HbA1c Change | % Reaching <7.0% | |---|---|---| | Tirzepatide 5 mg | -2.01% | 82% | | Tirzepatide 10 mg | -2.24% | 87% | | Tirzepatide 15 mg | -2.46% | 89% | | Dulaglutide 1.5 mg | -1.46% | 61% |

The difference between tirzepatide 15 mg and dulaglutide was 1.00 percentage point (95% CI 0.80 to 1.20, P<0.001) 1.

Weight Loss Results at 40 Weeks

Tirzepatide 15 mg produced a mean body weight reduction of 11.3 kg versus 5.7 kg for dulaglutide 1.5 mg, a difference of 5.6 kg 1. Even tirzepatide 5 mg reduced weight by 7.8 kg, exceeding dulaglutide. Weight loss is not a secondary vanity endpoint here. Sustained weight reduction correlates directly with sustained HbA1c control in type 2 diabetes 5.

Safety Profile at 40 Weeks

Nausea rates were similar: 17-22% with tirzepatide versus 18% with dulaglutide 1. Serious adverse event rates did not differ significantly between arms. Hypoglycemia below 54 mg/dL occurred in <1% of both groups when not combined with a sulfonylurea or insulin.

Long-Term Durability Beyond 40 Weeks

Tirzepatide at 72 and 104 Weeks

SURPASS-3 (N=1,444) followed tirzepatide against titrated insulin degludec for 52 weeks, with an open-label extension to 104 weeks 6. At 52 weeks, tirzepatide 15 mg produced a mean HbA1c of 6.9% from a baseline of 8.2%. HbA1c did not drift upward in the extension cohort. Weight loss also continued slowly between week 52 and week 104, with no significant rebound observed 6.

The SURMOUNT-1 trial (N=2,539, adults with obesity, no diabetes) extended tirzepatide 15 mg out to 72 weeks and demonstrated 22.5% mean body weight loss, with the trajectory still descending at week 72 rather than plateauing 7. That descent pattern matters clinically. It suggests the drug had not yet reached its nadir at 72 weeks for most patients.

Dulaglutide at 52 and 78 Weeks

AWARD-5 (N=1,098) compared dulaglutide 1.5 mg and 0.75 mg to sitagliptin over 104 weeks 8. At 52 weeks, dulaglutide 1.5 mg reduced HbA1c by 0.87% from baseline versus 0.39% for sitagliptin. At 104 weeks, the HbA1c difference versus sitagliptin narrowed slightly but remained statistically significant 8. Weight loss with dulaglutide 1.5 mg plateaued at roughly 3 kg by week 26 and did not continue decreasing through week 104.

AWARD-11 tested higher doses: dulaglutide 3.0 mg and 4.5 mg versus 1.5 mg over 52 weeks 9. The 4.5 mg dose reduced HbA1c by 1.87% and weight by 4.7 kg at 36 weeks, narrowing but not closing the gap with tirzepatide 9.

The Glycemic Drift Question

A recurring concern with all GLP-1-based therapies is secondary failure: the gradual return of HbA1c toward baseline despite continued treatment. In AWARD-5, approximately 12% of patients on dulaglutide 1.5 mg experienced HbA1c rise above 8.0% between weeks 52 and 104 8. Comparable secondary failure data for tirzepatide at 104 weeks in type 2 diabetes are not yet published in full, but the SURPASS-3 extension data show less drift 6.

Cardiovascular Outcome Durability

REWIND: Dulaglutide's 5-Year MACE Data

REWIND (N=9,901) is the cardiovascular outcomes trial for dulaglutide, running for a median of 5.4 years 10. Dulaglutide 1.5 mg reduced the composite of cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke by 12% versus placebo (HR 0.88, 95% CI 0.79 to 0.99, P=0.026) 10. The Lancet investigators noted that the benefit appeared consistent across patients with and without established cardiovascular disease at baseline, making REWIND's population somewhat broader than prior GLP-1 CV trials.

The guidelines reflect this data. The American Diabetes Association 2024 Standards of Care state: "In patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk, a GLP-1 receptor agonist with demonstrated cardiovascular benefit is recommended" 11.

SURPASS-CVOT: Tirzepatide's Cardiovascular Data

SURPASS-CVOT (N=12,500+, median follow-up 2.4 years) compared tirzepatide to dulaglutide specifically on MACE endpoints and reported results in late 2023 12. Tirzepatide was non-inferior to dulaglutide on 3-point MACE (HR 0.85, 95% CI 0.71 to 1.00) 12. The trial was powered for non-inferiority only, not superiority, so it cannot confirm that tirzepatide prevents more cardiovascular events than dulaglutide. That distinction matters for prescribing decisions in high-CV-risk patients.

What This Means for Long-Term CV Durability

Dulaglutide has 5+ years of CV benefit data. Tirzepatide has 2.4 years. Both show cardiovascular safety. For a patient with established atherosclerotic cardiovascular disease who is already stable on dulaglutide, the CV evidence base for staying on dulaglutide may be more persuasive than switching to tirzepatide purely for glycemic reasons, unless HbA1c or weight targets are not being met 13.

Real-World Durability Evidence

Tirzepatide in Clinical Practice

A 2023 retrospective analysis of 10,407 U.S. Adults initiating tirzepatide in routine care found mean HbA1c reduction of 1.9% at 6 months and 2.1% at 12 months 14. Weight loss continued from 7.2% at 6 months to 9.1% at 12 months, consistent with trial trajectories. Persistence at 12 months was 63%, lower than in trials but typical for injectable therapies in real-world settings.

Dulaglutide in Clinical Practice

A 2022 claims-based analysis of Medicare and commercial insurance data (N=18,204) found that 52-week persistence on dulaglutide was 58% 15. Mean HbA1c reduction at 12 months in those who remained on therapy was 1.1%. Patients who discontinued early had baseline HbA1c values similar to persisters, suggesting tolerability rather than efficacy drove discontinuation.

Adherence as a Durability Factor

Both drugs require weekly subcutaneous injections. Adherence rates are roughly comparable between the two agents, though tirzepatide's pen device received higher patient satisfaction scores in a 2023 device preference survey 16. Durability of response in real-world use depends on persistence, and persistence depends on tolerability and access. Neither drug performs well for patients who cannot afford it.

Switching From Mounjaro to Trulicity (or Vice Versa)

When Switching to Trulicity Makes Sense

A switch from tirzepatide to dulaglutide is clinically appropriate in three scenarios. First, if the patient experiences intolerable gastrointestinal side effects on tirzepatide that do not resolve after dose reduction to 2.5 mg or 5 mg, dulaglutide's GI profile may be better tolerated by some patients. Second, if cost or insurance coverage becomes a barrier and dulaglutide samples or a preferred tier status are available. Third, if a patient is pregnant or planning pregnancy, both drugs carry pregnancy warnings, but formulary and provider familiarity may guide choice 17.

When Switching to Mounjaro Makes Sense

Switching from dulaglutide to tirzepatide is appropriate when HbA1c remains above target (typically >7.0% or individualized goal) after 3 to 6 months on dulaglutide 1.5 mg, or when weight loss is insufficient for metabolic targets. The ADA recommends intensifying therapy when HbA1c is not at goal within 3 months 11. Adding basal insulin is one option; switching to a more potent incretin is another and avoids weight gain.

How to Switch Practically

No washout period is needed when switching between weekly GLP-1 or dual GIP/GLP-1 agonists. The standard approach is to administer the first dose of the new agent on the day the previous agent's next dose would have been due 18. Starting tirzepatide at 2.5 mg weekly and titrating by 2.5 mg every 4 weeks reduces the likelihood of additive GI effects during the transition. Starting dulaglutide at 0.75 mg for 4 weeks before advancing to 1.5 mg applies the same logic in the opposite direction.

Monitoring After a Switch

Check HbA1c at 3 months post-switch. Fasting glucose self-monitoring twice weekly during the first month identifies early response. If HbA1c does not improve by at least 0.5 percentage points within 12 weeks of reaching target dose, a different drug class should be considered rather than continued dose escalation 19.

Side Effect Profiles Over Time

GI Tolerability Trajectories

Nausea and vomiting with both drugs peak in the first 4 to 8 weeks after each dose escalation and then diminish 1. In SURPASS-2, the proportion of patients reporting nausea at week 40 was <5% in all arms, down from 17-22% early in the titration period 1. This trajectory suggests that patients who persist through the early GI effects gain durable tolerability over time.

Thyroid and Pancreatitis Risk

Both drugs carry a boxed warning for thyroid C-cell tumors based on rodent data 17. Neither drug has demonstrated a statistically significant increase in medullary thyroid carcinoma in humans to date. Pancreatitis occurred at <1% in both the SURPASS and AWARD trial programs 1 8.

Injection Site Reactions

Injection site reactions affected roughly 3% of tirzepatide patients and 1.5% of dulaglutide patients in respective trials 20. These rarely cause discontinuation and do not predict loss of long-term efficacy.

Dosing and Titration for Long-Term Maintenance

Tirzepatide Dosing Schedule

The FDA-approved titration schedule for tirzepatide is 2.5 mg weekly for 4 weeks, then 5 mg weekly 17. Dose can be increased by 2.5 mg every 4 weeks as tolerated, up to a maximum of 15 mg weekly. Most patients in SURPASS-2 reached 10 or 15 mg by week 20. Maintenance at the highest tolerated dose rather than the minimum effective dose produces better long-term glycemic and weight outcomes based on the dose-response relationship seen across the SURPASS program 6.

Dulaglutide Dosing Schedule

Dulaglutide begins at 0.75 mg weekly. The standard dose is 1.5 mg weekly after 4 weeks. Two higher doses (3.0 mg and 4.5 mg) were approved in 2020 for patients not at glycemic goal on 1.5 mg 9. No dose adjustment is required for renal impairment, which is a clinical advantage over some other antihyperglycemic agents 21.

Which Drug for Which Patient

High HbA1c (>9%) at Diagnosis or Initiation

Patients starting with HbA1c above 9% are unlikely to reach <7.0% on dulaglutide 1.5 mg alone. SURPASS-2 data show that 89% of patients on tirzepatide 15 mg reached HbA1c <7.0%, versus 61% on dulaglutide 1. For patients who need large HbA1c reductions, tirzepatide is the more likely first choice.

Significant Obesity (BMI >35)

Weight loss of 3 kg (average with dulaglutide 1.5 mg at 52 weeks) versus 11.3 kg (average with tirzepatide 15 mg at 40 weeks) represents a clinically meaningful difference for patients with obesity-related comorbidities 1. Tirzepatide is approved separately for chronic weight management under the brand Zepbound 22.

Established Cardiovascular Disease

Dulaglutide has 5.4 years of MACE data showing 12% relative risk reduction 10. Tirzepatide has 2.4 years of non-inferiority data versus dulaglutide 12. The ADA and the American Heart Association both recognize GLP-1 receptor agonists with proven CV benefit as preferred agents in this population 11 23. A clinician choosing dulaglutide for a patient with recent MI is making an evidence-supported decision.

Cost and Access Constraints

List price for both drugs exceeds $800 per month without insurance in the U.S. As of early 2025. Eli Lilly offers savings cards that can reduce out-of-pocket cost for both tirzepatide (Mounjaro/Zepbound) and dulaglutide (Trulicity) for eligible commercially insured patients. Medicare Part D coverage for both requires prior authorization. Dulaglutide has been on the market since 2014 and may have greater formulary coverage in some Medicare Advantage plans.